Related Experiment Video

Updated: Jul 10, 2026

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

The pharmacology of endosomal TLR agonists in viral disease

D R Averett1, S P Fletcher, W Li

  • 1Anadys Pharmaceuticals, Inc., 3115 Merryfield Row, San Diego, CA 92121, USA. daverett@anadyspharma.com

Biochemical Society Transactions
|November 23, 2007
PubMed

Insights

Endosomal Toll-like receptors (TLRs) and their agonists show therapeutic potential, particularly in viral diseases. Different TLR agonists induce varied innate immune responses, impacting drug development and pharmacological profiles.

Area of Science:

  • Immunology
  • Pharmacology
  • Virology

Background:

  • Endosomal Toll-like receptors (TLRs) and their natural ligands are key targets for therapeutic development.
  • Clinical studies have explored agents now recognized as endosomal TLR agonists.
  • Viral diseases have shown clinical responses to agonists of TLR3, TLR7, TLR7/8, and TLR9.

Purpose of the Study:

  • To review the therapeutic potential of endosomal TLR agonists.
  • To analyze the clinical effects and immune responses induced by various TLR agonists.
  • To discuss the implications of TLR targeting for drug development.

Main Methods:

  • Literature review of pre-clinical and clinical studies on endosomal TLR agonists.
  • Analysis of reported clinical effects in viral diseases.
  • Examination of biomarker signatures, including type 1 interferon induction.

Main Results:

  • Agonists of TLR3, TLR7, TLR7/8, and TLR9 have demonstrated clinical efficacy in viral diseases.
  • Imiquimod, a TLR7 agonist, is approved for topical treatment of human papillomavirus infections.
  • A multifaceted innate immune response, characterized by type 1 interferon induction, is a common signature.

Conclusions:

  • Endosomal TLR agonists offer significant therapeutic promise, especially for viral infections.
  • Differences in pharmaceutical properties and cellular TLR distribution influence the pharmacological profiles of these drugs.
  • Targeting endosomal TLRs represents a viable strategy for developing novel antiviral therapies.

More Related Videos

Fluorescence Assays for the Study of Mycobacterium tuberculosis Interaction with the Immune Receptor SLAMF107:42

Fluorescence Assays for the Study of Mycobacterium tuberculosis Interaction with the Immune Receptor SLAMF1

Published on: February 28, 2025

Engineering Antiviral Agents via Surface Plasmon Resonance13:00

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

Related Concept Videos

Receptor-mediated Endocytosis01:38

Receptor-mediated Endocytosis

Overview
Receptor-mediated Endocytosis01:20

Receptor-mediated Endocytosis

Receptor-mediated endocytosis is when bulk amounts of specific molecules are imported into a cell after binding to cell surface receptors. The molecules bound to these receptors are taken into the cell through inward folding of the cell surface membrane, which is eventually pinched off into a vesicle within the cell. Structural proteins, such as clathrin, coat the budding vesicle.
Clathrin-Mediated Endocytosis of LDL
One well-characterized example of receptor-mediated endocytosis is the...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.